Efavirenz and Ritonavir on Human Brain P-Glycoprotein

• Status: Completed
• Trial end date: 2016-08-01
• Target enrollment: 0
• Participant gender: All

Summary

To determine the effects of ritonavir and efavirenz on the activity of P-glycoprotein in human brain.

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Washington University School of Medicine
• Treatments: Antidiarrheals; Efavirenz; Krestin; Loperamide; Ritonavir

Criteria

Inclusion Criteria:

• Male or non-pregnant female, 18-40 yr old

• Good general health with no remarkable medical conditions

• BMI < 33

• Provide informed consent

Exclusion Criteria:

• Known history of liver or kidney disease

• History of major medical conditions

• HIV seropositive

• Fasting blood glucose > 110 mg/dl

• Family history of type 2 diabetes

• Use of prescription or non prescription medications, herbals or foods known to be metabolized by or altering P-glycoprotein or CYP3A activity (hormonal birth control medications are acceptable if alternative means of contraception are used)

• Females who are pregnant or nursing

• Females taking hormonal contraceptives who are unwilling to use alternative means of contraception

• Contraindications to MRI

• Contraindications to PET scanning